

2002282

Congenital Adrenal Hyperplasia Panel, 11-Beta Hydroxylase Deficiency

CAH 11-B HYDROX

Reference Interval:

Test Number	Components	Reference Interval		
2001638	Androstenedione	Effective August 19, 2013		
		Age	Female	Male
		Premature Infants, 26-28 weeks-Day 4	0.92-2.82 ng/mL	0.92-2.82 ng/mL
		Premature Infants, 31-35 weeks-Day 4	0.80-4.46 ng/mL	0.80-4.46 ng/mL
		Full-term Infants, 1-7 days	0.20-2.90 ng/mL	0.20-2.90 ng/mL
		8-30 days	0.18-0.80 ng/mL	0.18-0.80 ng/mL
		1-5 months	0.06-0.68 ng/mL	0.06-0.68 ng/mL
		6-24 months	Less than 0.15 ng/mL	0.03-0.15 ng/mL
		2-3 years	Less than 0.16 ng/mL	Less than 0.11 ng/mL
		4-5 years	0.02-0.21 ng/mL	0.02-0.17 ng/mL
		6-7 years	0.02-0.28 ng/mL	0.01-0.29 ng/mL
		8-9 years	0.04-0.42 ng/mL	0.03-0.30 ng/mL
		10-11 years	0.09-1.23 ng/mL	0.07-0.39 ng/mL
		12-13 years	0.24-1.73 ng/mL	0.10-0.64 ng/mL
		14-15 years	0.39-2.00 ng/mL	0.18-0.94 ng/mL
		16-17 years	0.35-2.12 ng/mL	0.30-1.13 ng/mL
		18-39 years	0.26-2.14 ng/mL	0.33-1.34 ng/mL
		40 years and older	0.13-0.82 ng/mL	0.23-0.89 ng/mL
		Pre-menopausal	0.26-2.14 ng/mL	Does Not Apply
Postmenopausal	0.13-0.82 ng/mL	Does Not Apply		
Tanner Stage I	0.05-0.51 ng/mL	0.04-0.32 ng/mL		
Tanner Stage II	0.15-1.37 ng/mL	0.08-0.48 ng/mL		
Tanner Stage III	0.37-2.24 ng/mL	0.14-0.87 ng/mL		
Tanner Stage IV-V	0.35-2.05 ng/mL	0.27-1.07 ng/mL		
0092332	17-Hydroxyprogesterone Quantitative by HPLC-MS/MS, Serum or Plasma	Effective August 19, 2013		
		Age	Female	Male
		Premature (26-28 weeks)	124-841 ng/dL	124-841 ng/dL
		Premature (29-35 weeks)	26-568 ng/dL	26-568 ng/dL
		Full term Day 3	7-77 ng/dL	7-77 ng/dL
		4 days-30 days	7-106 ng/dL	Less than 200 ng/dL
		1 month-2 months	13-106 ng/dL	Less than 200 ng/dL
		3 months-5 months	13-106 ng/dL	3-90 ng/dL
		6 months-1 year	Less than or equal to 148 ng/dL	Less than or equal to 148 ng/dL
		2-3 years	Less than or equal to 256 ng/dL	Less than or equal to 228 ng/dL
		4-6 years	Less than or equal to 299 ng/dL	Less than or equal to 208 ng/dL
		7-9 years	Less than or equal to 71 ng/dL	Less than or equal to 63 ng/dL
		10-12 years	Less than or equal to 129 ng/dL	Less than or equal to 79 ng/dL
		13-15 years	9-208 ng/dL	9-140 ng/dL
		16-17 years	Less than or equal to 178 ng/dL	24-192 ng/dL
		18 years and older	Less than 207 ng/dL	Less than 139 ng/dL
		Follicular	15-70 ng/dL	Does Not Apply
		Luteal	35-290 ng/dL	Does Not Apply
		Tanner Stage I	Less than or equal to 74 ng/dL	Less than or equal to 62 ng/dL
Tanner Stage II	Less than or equal to 164 ng/dL	Less than or equal to 104 ng/dL		
Tanner Stage III	13-209 ng/dL	Less than or equal to 151 ng/dL		
Tanner Stage IV-V	7-170 ng/dL	20-173 ng/dL		
0081058	Testosterone (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)	Effective August 19, 2013		
		Age	Female	Male
		Premature (26-28 weeks)	5-16 ng/dL	59-125 ng/dL
		Premature (31-35 weeks)	5-22 ng/dL	37-198 ng/dL
		Newborn	20-64 ng/dL	75-400 ng/dL
		1-5 months	Less than 20 ng/dL	14-363 ng/dL
		6-24 months	Less than 9 ng/dL	Less than 37 ng/dL
		2-3 years	Less than 20 ng/dL	Less than 15 ng/dL
		4-5 years	Less than 30 ng/dL	Less than 19 ng/dL
		6-7 years	Less than 7 ng/dL	Less than 13 ng/dL

HOTLINE: Effective February 22, 2022

		8-9 years	1-11 ng/dL	2-8 ng/dL
		10-11 years	3-32 ng/dL	2-165 ng/dL
		12-13 years	6-50 ng/dL	3-619 ng/dL
		14-15 years	6-52 ng/dL	31-733 ng/dL
		16-17 years	9-58 ng/dL	158-826 ng/dL
		18-39 years	9-55 ng/dL	300-1080 ng/dL
		40-59 years	9-55 ng/dL	300-890 ng/dL
		60 years and older	5-32 ng/dL	300-720 ng/dL
		Premenopausal (18 years and older)	9-55 ng/dL	Does Not Apply
		Postmenopausal	5-32 ng/dL	Does Not Apply
		Tanner Stage I	2-17 ng/dL	2-15 ng/dL
		Tanner Stage II	5-40 ng/dL	3-303 ng/dL
		Tanner Stage III	10-63 ng/dL	10-851 ng/dL
		Tanner Stage IV-V	11-62 ng/dL	162-847 ng/dL
0092331	11-Deoxycortisol Quantitative by HPLC- MS/MS, Serum or Plasma	Effective August 19, 2013		
		Age	Female	Male
		Premature (26-28 weeks)	110-1376 ng/dL	110-1376 ng/dL
		Premature (29-36 weeks)	70-455 ng/dL	70-455 ng/dL
		Full Term (1-5 months)	10-200 ng/dL	10-200 ng/dL
		6-11 months	10-276 ng/dL	10-276 ng/dL
		1-3 years	7-247 ng/dL	7-202 ng/dL
		4-6 years	8-291 ng/dL	8-235 ng/dL
		7-9 years	Less than or equal to 94 ng/dL	Less than or equal to 120 ng/dL
		10-12 years	Less than or equal to 123 ng/dL	Less than or equal to 92 ng/dL
		13-15 years	Less than or equal to 107 ng/dL	Less than or equal to 95 ng/dL
		16-17 years	Less than or equal to 47 ng/dL	Less than or equal to 106 ng/dL
		18 years and older	Less than 33 ng/dL	Less than 50 ng/dL
		Tanner Stage I	Less than or equal to 94 ng/dL	Less than or equal to 105 ng/dL
		Tanner Stage II	Less than or equal to 136 ng/dL	Less than or equal to 108 ng/dL
		Tanner Stage III	Less than or equal to 99 ng/dL	Less than or equal to 111 ng/dL
		Tanner Stage IV & V	Less than or equal to 50 ng/dL	Less than or equal to 83 ng/dL
		After metyrapone stimulation	Greater than 8000 ng/dL	Greater than 8000 ng/dL
2001640	Dehydroepiandrosterone, Serum or Plasma	Effective August 19, 2013		
		Age	Female	Male
		Premature	Less than 40 ng/mL	Less than 40 ng/mL
		0-1 day	Less than 11 ng/mL	Less than 11 ng/mL
		2-6 days	Less than 8.7 ng/mL	Less than 8.7 ng/mL
		7 days-1 month	Less than 5.8 ng/mL	Less than 5.8 ng/mL
		1-5 months	Less than 2.9 ng/mL	Less than 2.9 ng/mL
		6-24 months	Less than 1.9 9 ng/mL	Less than 2.5 ng/mL
		2-3 years	Less than 0.85 ng/mL	Less than 0.63 ng/mL
		4-5 years	Less than 1.03 ng/mL	Less than 0.95 ng/mL
		6-7 years	Less than 1.79 ng/mL	0.06-1.93 ng/mL
		8-9 years	0.14-2.35 ng/mL	0.10-2.08 ng/mL
		10-11 years	0.43-3.78 ng/mL	0.32-3.08 ng/mL
		12-13 years	0.89-6.21 ng/mL	0.57-4.10 ng/mL
		14-15 years	1.22-7.01 ng/mL	0.93-6.04 ng/mL
		16-17 years	1.42-9.00 ng/mL	1.17-6.52 ng/mL
		18-39 years	1.33-7.78 ng/mL	1.33-7.78 ng/mL
		40 years and older	0.63-4.70 ng/mL	0.63-4.70 ng/mL
		Postmenopausal	0.60-5.73 ng/mL	Does Not Apply
		Tanner Stage I	0.14-2.76 ng/mL	0.11-2.37 ng/mL
		Tanner Stage II	0.83-4.87 ng/mL	0.37-3.66 ng/mL
		Tanner Stage III	1.08-7.56 ng/mL	0.75-5.24 ng/mL
		Tanner Stage IV-V	1.24-7.88 ng/mL	1.22-6.73 ng/mL

Interpretive Data:

Free or bioavailable testosterone measurements may provide supportive information.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.

Change the charting name for component 0081058, Testosterone, LC-MS/MS from Testosterone, LC-MS/MS to Testosterone by Mass Spec.



HOTLINE: Effective February 22, 2022